330 related articles for article (PubMed ID: 10450751)
1. Transplant characteristics: minimal residual disease and impaired megakaryocytic colony growth as sensitive parameters for predicting relapse in acute myeloid leukemia.
Reichle A; Rothe G; Krause S; Zaiss M; Ullrich H; Schmitz G; Andreesen R
Leukemia; 1999 Aug; 13(8):1227-34. PubMed ID: 10450751
[TBL] [Abstract][Full Text] [Related]
2. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia.
Venditti A; Buccisano F; Del Poeta G; Maurillo L; Tamburini A; Cox C; Battaglia A; Catalano G; Del Moro B; Cudillo L; Postorino M; Masi M; Amadori S
Blood; 2000 Dec; 96(12):3948-52. PubMed ID: 11090082
[TBL] [Abstract][Full Text] [Related]
3. Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation.
Venditti A; Maurillo L; Buccisano F; Del Poeta G; Mazzone C; Tamburini A; Del Principe MI; Consalvo MI; De Fabritiis P; Cudillo L; Picardi A; Franchi A; Lo-Coco F; Amadori S
Leukemia; 2003 Nov; 17(11):2178-82. PubMed ID: 14576731
[TBL] [Abstract][Full Text] [Related]
4. Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia.
Demirer T; Petersen FB; Bensinger WI; Appelbaum FR; Fefer A; Rowley S; Sanders J; Chauncey T; Storb R; Lilleby K; Buckner CD
Bone Marrow Transplant; 1996 Jul; 18(1):29-34. PubMed ID: 8831992
[TBL] [Abstract][Full Text] [Related]
5. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
Maurillo L; Buccisano F; Spagnoli A; Del Poeta G; Panetta P; Neri B; Del Principe MI; Mazzone C; Consalvo MI; Tamburini A; Ottaviani L; Fraboni D; Sarlo C; De Fabritiis P; Amadori S; Venditti A
Haematologica; 2007 May; 92(5):605-11. PubMed ID: 17488683
[TBL] [Abstract][Full Text] [Related]
7. Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden.
Feller N; Jansen-van der Weide MC; van der Pol MA; Westra GA; Ossenkoppele GJ; Schuurhuis GJ
Exp Hematol; 2005 Jan; 33(1):120-30. PubMed ID: 15661405
[TBL] [Abstract][Full Text] [Related]
8. Multicenter randomized phase II trial of idarubicin vs mitoxantrone, combined with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood stem cell transplantation in elderly patients with acute myeloid leukemia.
Archimbaud E; Jehn U; Thomas X; De Cataldo F; Fillet G; Belhabri A; Peaud PY; Martin C; Amadori S; Willemze R
Leukemia; 1999 Jun; 13(6):843-9. PubMed ID: 10360370
[TBL] [Abstract][Full Text] [Related]
9. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP; Mannis GN; Wood BL; Radich JP; Hwang J; Ramos NR; Andreadis C; Damon L; Logan AC; Martin TG; Hourigan CS
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1974-1982. PubMed ID: 27544285
[TBL] [Abstract][Full Text] [Related]
10. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
Thomas X; Suciu S; Rio B; Leone G; Broccia G; Fillet G; Jehn U; Feremans W; Meloni G; Vignetti M; de Witte T; Amadori S
Haematologica; 2007 Mar; 92(3):389-96. PubMed ID: 17339189
[TBL] [Abstract][Full Text] [Related]
11. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies.
Motta MR; Mangianti S; Rizzi S; Ratta M; Campanini E; Fortuna A; Fogli M; Tura S; Lemoli RM
Exp Hematol; 1997 Nov; 25(12):1261-9. PubMed ID: 9357970
[TBL] [Abstract][Full Text] [Related]
13. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
[TBL] [Abstract][Full Text] [Related]
14. The impact of pre-transplant minimal residual disease on outcome of intensified myeloablative cord blood transplant for acute myeloid leukemia in first or second complete remission.
Zheng C; Zhu X; Tang B; Zhang L; Geng L; Liu H; Sun Z
Leuk Lymphoma; 2016; 57(6):1398-405. PubMed ID: 26690538
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood stem cells mobilized from patients with acute myeloid leukaemia have different platelet repopulating abilities compared with those mobilized from patients with other diseases.
Roberts MM; Dyson PG; Willson K; Juttner CA; To LB
Bone Marrow Transplant; 1996 Jul; 18(1):41-5. PubMed ID: 8831994
[TBL] [Abstract][Full Text] [Related]
16. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S
Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929
[TBL] [Abstract][Full Text] [Related]
17. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
18. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Del Principe MI; Del Poeta G; Spagnoli A; Panetta P; Ammatuna E; Neri B; Ottaviani L; Sarlo C; Venditti D; Quaresima M; Cerretti R; Rizzo M; de Fabritiis P; Lo Coco F; Arcese W; Amadori S; Venditti A
J Clin Oncol; 2008 Oct; 26(30):4944-51. PubMed ID: 18606980
[TBL] [Abstract][Full Text] [Related]
19. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
20. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia.
Feller N; van der Pol MA; van Stijn A; Weijers GW; Westra AH; Evertse BW; Ossenkoppele GJ; Schuurhuis GJ
Leukemia; 2004 Aug; 18(8):1380-90. PubMed ID: 15201848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
